MedTrace Logo

Pragmatic Trial of Messaging to Providers About Treatment of Heart Failure

NCT04514458 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 1410

Last updated 2025-07-01

Study results available
· View outcomes & findings →

Summary

A randomized controlled trial to compare the efficacy of an electronic health record-based alert informing providers about evidence-based medications for HFrEF versus usual care (no alert) in outpatient clinics across a single health system.

Conditions

  • Heart Failure With Reduced Ejection Fraction

Interventions

OTHER

Best practice alert for the notification of patient HFrEF and recommended evidence-based therapies (NO drugs are being administered in this trial)

Providers will receive a best practice alert for each of their eligible patients upon opening of the order entry screen in the patient's medical record. The alert will inform the provider to the presence of HFrEF and of the patient's current left ventricular ejection fraction and current evidence-based medications for HFrEF. It will also provide access to an order set with recommended evidence-based HFrEF therapies as well as a link to the best available guideline-recommended information regarding the treatment of heart failure.

Sponsors & Collaborators

  • AstraZeneca

    collaborator INDUSTRY

  • Yale University

    lead OTHER

Principal Investigators

  • Tariq Ahmad, MD MPH · Yale University

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-01-25
Primary Completion
2021-11-20
Completion
2022-10-20

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04514458 on ClinicalTrials.gov